<DOC>
	<DOCNO>NCT01218880</DOCNO>
	<brief_summary>Phase I trail conduct evaluate safety M2ES combination gemcitabine locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Study With M2ES Gemcitabine Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Phase I trail conduct determine MTD safety M2ES ( administer intravenous infusion Days 1,8,15,21of 28-day cycle ) combination gemcitabine ( 1000 m/m2 ) . Gemcitabine administer intravenous infusion Days 1 , 8 , 15 28-day cycle , time determine safety efficiency combine regime .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1. patient histologically cytologically confirm pancreatic adenocarcinoma amenable potentially curative surgery . 2 . No prior chemotherapy allow . 3 . Prior radiation therapy allow provide site measurable disease locate within radiation port . 4 . 18 60 year age 5 . Karnofsky performance status ( KPS ) 60100 point 6 . Unidimensionally measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 7 . Adequate hematologic , renal , hepatic function require deWned follow : WBC ≥4×109/L , absolute neutrophil count ≥ 1.5×109/L , platelet count ≥100×109/L , hemoglobin ≥ 9g/dL , total bilirubin ≤2 upper limit normal [ ULN ] , AST ≤ 1.5 ULN , ≤ 3 ULN evidence liver metastasis ; alkaline phosphatase ≤ 1.5 ULN , ≤ 3 ULN evidence liver Metastases ; creatinine clearance ≥50 mL/min . 8. life expectancy least 12 week . 9 . All patient provide write informed consent accord federal institutional guideline . 1. patient clinically apparent CNS disease ( primary brain tumor , tumor relate apoplexy , CNS metastases , carcinomatous meningitis . ) 2. another active malignancy , history malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix . 3. 4 week interval last administration target therapy regimen study entry . 4. radiation therapy complete 4 week enrollment . 5. major surgery within prior 4 week ; 6. participate clinical trial within prior 4 week ; 7 . Pregnant lactating woman . 8. tumor involvement major blood vessel 9. uncontrolled intercurrent illness following : prior ongoing uncontrolled hypertension ; angina pectoris ; congestive cardiac failure ; myocardial ischemia , infarction , uncompensated coronary artery disease within past 6 month ; Uncontrolled arrhythmia ; Uncontrolled diabetes mellitus ; Uncontrolled infection . 10. chronic renal disease . 11. urine protein ≥ 500 mg 24 hour ; 12. prior history gastrointestinal bleeding , hemoptysis , bleed diathesis . 13. pulmonary embolus , deep venous thrombosis 14 . ECG : QTC ≥ 480 m 15 . Patients therapeutic dos heparin antiplatelet agent . 16 . Patients receive thrombolytic agent require fulldose anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>